Skip to content

Management of Post-operative Respiratory Failure by Using NIV and High Velocity Nasal Insufflation (HVNI)

A Prospective, Randomized Controlled Trial Comparing Noninvasive Ventilation (NIV) Versus High-Velocity Nasal Cannula (HVNC) in the Management of Acute Post-Operative Respiratory Failure

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06988111
Enrollment
180
Registered
2025-05-23
Start date
2025-07-01
Completion date
2026-12-01
Last updated
2025-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Failure Without Hypercapnia, Respiratory Failure With Hypercapnia, Postoperative Respiratory Complication

Brief summary

Postoperative respiratory failure (PORF) remains a critical driver of morbidity, mortality, and incremental care costs in surgical populations. Traditional escalation often involves invasive mechanical ventilation, which is associated with ventilator-associated pneumonia (VAP), prolonged intensive care unit (ICU) stays, and increased resource burden.

Detailed description

Noninvasive ventilation (NIV) and high-flow nasal cannula (HFNC) have both been shown to improve oxygen levels effectively and reduce the need for reintubation in various patient groups. However, head-to-head data in patients with obstructive or restrictive pulmonary function (PORF) are scarce. This protocol employs a robust and scalable design to generate high-quality evidence, empower perioperative stakeholders, and optimize patient-centric respiratory strategies. We hypothesize that NIV will reduce 72-hour reintubation rates compared to HFNC, translating into shorter ICU stays and lower costs. Methodology & Operational Workflow * Screening & Consent Identify eligible patients in the post-anesthesia care unit (PACU) or ICU. Obtain informed consent from the patient or legal surrogate. * Baseline Assessment The baseline assessment includes demographics, comorbidities, and surgical data, as well as baseline arterial blood gases (ABG), vital signs, and comfort scores. * Randomization & Initiation Allocate via a secure web-based randomization module. Initiate assigned respiratory support within 30 minutes of notification. * Monitoring & Data Collection The patient is receiving continuous pulse oximetry and respiratory rate monitoring. ABGs and fraction of inspired oxygen (FIO2) at 1 hour, 6 hours, and 24 hours. Comfort scores every six hours. Record interface-related adverse events. \- Escalation Criteria The patient exhibits persistent partial arterial oxygen pressure/fraction of inspired oxygen ratio (PaO2/FiO2) levels of less than 100, even at maximal settings. Hemodynamic instability occurs due to the use of new-onset vasopressors. Deterioration leading to invasive ventilation → classified as reintubation. * Weaning Protocol. Transition to standard oxygen therapy when the flow or pressure is minimal. * Follow-Up & Discharge Track ICU length of stay (LOS), hospital LOS, and ventilation-free days (VFD). Keep a record of the 30-day survival rate and any readmissions. * Statistical Analysis Plan Primary Endpoint: Compare reintubation rates using a χ² test; report the risk difference and 95% confidence interval. * Missing Data: Multiple imputation for datasets with ≤ 5% missing data; sensitivity analysis for worst-case scenarios. * Interim Analysis: After 50% enrollment, the Data Safety and Monitoring Board (DSMB) reviews efficacy and futility, using O'Brien-Fleming boundaries.

Interventions

DEVICEBIPAP

The second arm (NIV group) will be managed by BIPAP device for post-operative respiratory failure

DEVICEVapotherm

The first arm (HVNC group) will be managed by Vapotherm device for post-operative respiratory failure

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

The patient with operative respiratory failure will be compared using NIV and High velocity nasal cannula devices

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age above 18 years * within 48 hours after major surgery * PAO2/FIO2 less than 200 * Signs of respiratory distress and respiratory rate (RR) more than 25 cycles/minute

Exclusion criteria

* Age below 18 years * Pregnant ladies * Orofacial trauma or burns * Active Gastrointestinal bleeding

Design outcomes

Primary

MeasureTime frameDescription
Weaning successAt 48 hours and then daily for 28 days.The primary outcome will be comparing the weaning success (in days) for both arms of the study group. This will be accessed after 48 hours and on a daily basis until the weaning criteria are met or for 28 days.

Countries

Egypt

Contacts

Primary ContactAhmad M. Shaddad, MD
shaddad_ahmad@aun.edu.eg+201111171930

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026